KLOW 80mg

KLOW 80mg — High-Dose Multi-Peptide Research Blend

KLOW 80mg is a high-dose multi-compound research blend formulated for researchers studying the combined effects of complementary regenerative and repair peptides at elevated concentrations. The blend includes BPC-157 and TB-500 as principal compounds alongside additional research peptides, co-lyophilised at ≥98% purity per compound in a single vial.

The high total dose (80mg) makes KLOW of particular interest for research protocols requiring extended duration, higher-concentration applications, or studies investigating dose-response relationships across multi-pathway regenerative endpoints. UK-dispatched by OL Research. For laboratory research use only.

Research Context

Multi-peptide blends at elevated doses are studied for several distinct research purposes:

• Dose-response research — Higher-concentration blends allow researchers to construct dose-response curves across a wider concentration range within the same compound supply
• Extended protocol studies — A single high-dose vial reduces reconstitution frequency in longitudinal research protocols requiring consistent compound ratios over extended timeframes
• Multi-pathway synergy investigation — The inclusion of BPC-157, TB-500, and additional compounds allows researchers to study potential interactions across multiple repair and regenerative signalling pathways simultaneously
• Comparative dosing studies — Comparing outcomes between standard-dose individual compounds (e.g., BPC-157 + TB-500 20mg) and higher-concentration blends in matched tissue models

Product Specifications

Key Questions

How does KLOW differ from the BPC-157 + TB-500 blend?
The BPC-157 + TB-500 blend is a 1:1 formulation at standard research doses. KLOW 80mg is a higher-dose multi-compound blend with a broader peptide composition. KLOW is selected for protocols requiring higher concentrations, extended research durations, or multi-compound interactions beyond the BPC-157/TB-500 pairing.

Is KLOW suitable for dose-response studies?
Yes — the higher total quantity allows researchers to set up concentration gradients across a wider range than a single standard-dose vial would permit, making it a practical choice for EC50/IC50-type studies or dose escalation protocols.

Is this for human use?
No. Supplied strictly for laboratory research use only.

Why a 4-Compound Multi-Pathway Blend

KLOW 80mg is the highest-complexity research blend in the OL Research catalogue, combining four compounds across four distinct molecular mechanisms in a single co-lyophilised preparation:

• BPC-157 (10mg) — angiogenesis (VEGF), nitric oxide pathway modulation, gastrointestinal mucosal repair
• GHK-Cu (50mg) — copper-binding tripeptide; collagen synthesis, extracellular matrix remodelling, dermal research
• TB-500 (10mg) — actin sequestration, cell migration, cytoskeletal remodelling
• KPV (10mg) — α-MSH-derived tripeptide; NF-κB inhibition, inflammatory pathway downregulation, gut mucosal research

The addition of KPV is what distinguishes KLOW from the simpler tri-compound GLOW blend — it introduces an explicit anti-inflammatory dimension that the three other compounds lack at meaningful potency. This makes KLOW of particular interest to researchers studying repair and regeneration in the context of inflammatory injury models, where the inflammatory and reparative pathways co-occur and benefit from concurrent investigation.

The 80mg total dose also makes KLOW the most cost-effective per-mg blend for extended-protocol research, dose-response curves, and multi-arm comparative studies where total compound consumption is high. For two-compound work without the copper or anti-inflammatory arms, see BPC-157 + TB-500 20mg; for three-compound work without KPV, see GLOW 70mg.

Related Research Compounds

• BPC-157 + TB-500 20mg — Standard-dose BPC-157 + TB-500 research blend
• BPC-157 10mg — Individual compound
• TB-500 10mg — Individual compound

⚠️ For laboratory and in-vitro research use only. Not for human consumption, veterinary use, or clinical application.